Cave Creek, Arizona--(Newsfile Corp. - May 9, 2018) - Endexx Corporation (OTC Pink: EDXC), a provider of innovative phytonutrient-based food and nutritional products, has completed its acquisition of Go Green Global Enterprises Inc. to secure an international distribution hub in Jamaica for its entire array of cannabidiol (CBD) based products to key markets, among which are Canada, Europe, South and Central America and the Caribbean. By having a company based in Jamaica, Endexx can legally export its CBD products and Innovative Autospense™ products internationally, possibly increasing substantially its revenue and earnings.
Endexx is pursuing multiple licenses in Jamaica to establish a vertical market to grow, process, transport, dispense, sell, and export its entire array of products, both current and future. The Company's CBD Unlimited line of cannabidiol (CBD) Cannsummable Portfolio products includes its formulated topical CBD balm and mist, travel sleep aid, teas, oils, capsules, soft chews for dogs and cats, and other products that provide key benefits to users.
Endexx can now legally export its CBD products and Innovative Autospense™ products internationally, which is expected to substantially increase revenue and earnings. The acquisition is expected to substantially drive the company's growth strategy as it also establishes a new market for Endexx's Autospense technology, an industrial-grade automated asset protection and dispensing solution aimed at the retail and pharmacy markets.
Todd Davis, Chief Executive Officer of Endexx, said, "During the past several months, we have secured key relationships and business partners in Jamaica to ensure our success with operations, compliance, and governmental affairs, education and medical resourcing and exportation procedures. As a result, we have formed strong alliances within the country that afford us the opportunity to quickly scale up all aspects of the business for our product and product lines so we can begin exporting our products internationally. Given the significant demand and sizeable market opportunity for our products globally, we expect to significantly ramp revenue and earnings in the coming quarters."
According to Forbes, cannabis sales internationally currently exceed $10 billion and are projected to reach $31.5 billion by 2021. A separate report published by Energias Market Research, cited that the global medical cannabis market is expected to grow significantly from $8.28 billion in 2017 to $28.07 billion in 2024 at a CAGR of 19.1% from 2018 to 2024.
Endexx, with its collaborative partners and consultants, develops and distributes two consumable product lines derived from industrial hemp, which is organic and naturally rich in phytocannabinoids. Phyto-Bites® is its CBD-infused soft chews for dogs and cats. The dog treats are formulated to promote health and support the reduction of separation anxiety, pain and inflammation. The company also has two technology products and services that launched in 2014 — the m3hub and the AutoSpense™. Both products provide essential solutions to promote regulatory compliance and full accountability through "seed to sale" inventory management and an "end of sale" technology integration. Based on principles developed by the pharmacological industry, the m3hub platform is the first standardized software solution for tracking pharmaceutical-grade marijuana that maintains compliance with federal, state and local regulations. It is intended to provide a smooth transition to eventual federal mandates. The AutoSpense™ is a commercial-grade inventory control and dispensing device that provides up-to-the-minute accounting details and ensures both product and patient security. By automating the dispensing process, AutoSpense™ increases productivity and reduces costs for marijuana retailers, while enhancing their service quality by reducing transaction time for customers. Websites include www.cbdunlimited.com, www.endexx.com and www.phytobites.com.
Safe Harbor Notice
This press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future development activities, and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the company's ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with the company's business and finances in general, including the ability to continue and manage its growth, competition, global economic conditions and other factors discussed in detail in the Company's periodic filings with the Securities and Exchange Commission. The company undertakes no obligation to update any forward-looking statements.
For further investor and media information, contact:
Chairman & CEO